The Low Institute for Therapeutics (LIFT) is a non-profit drug discovery institute dedicated to reducing human suffering and mortality through research and drug discovery. The institute was founded to advance and accelerate the pioneering drug discovery work conducted at Purdue University in the lab of Dr Phil Low, Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry and Biochemistry by bridging the gap between academic discovery and for-profit clinical development.
With over 50 years of research and drug discovery experience, the Low Lab at Purdue has discovered three FDA approved drugs (PLUVICTO, LOCAMETZ, CYTALUX) and five investigational drugs currently in human clinical trials, and holds over 100 approved patents.
Precision medicines which selectively attack cancer cells while sparing healthy tissue
Read more >Drug-based strategies that promote tissue and organ repair, including bone and soft tissue regeneration.
Read more >Therapies targeting cellular mechanisms
behind fibrosis across organ systems
New mechanisms of action to treat diseases such as malaria and sickle cell disease
Read more >Compounds that reprogram immune cells to combat inflammation, cancer, and autoimmune disorders
Read more >LIFT is focusing on disease areas that matter most, including hard-to-treat cancers, chronic kidney disease, pulmonary fibrosis, heart failure, rheumatoid arthritis, organ transplant rejection, fatty liver disease, Alzheimer’s disease, sickle cell disease and bone fractures.
Discover more >
Know us better
The Low Institute for Therapeutics (LIFT) is a non-profit drug discovery institute dedicated to reducing human suffering and mortality through research and drug discovery.
Co-Founder and Chairman of the Board
Dr. Philip Low is the Presidential Scholar for Drug Discovery and the RC Corley Distinguished Professor of Chemistry at Purdue University, where he directs a lab of ~35 graduate students/postdocs and ~50 undergraduate researchers.
Co-Founder and Founding Donor
Jeff Pickett is a Co-Founder at the Low Institute for Therapeutics (LIFT). He is the founder of Connor Group, a premier global professional services firm specializing in technical accounting, financial operations, and IPO services.
Co-Founder and Managing Director
Benjamin Lundgren is Managing Director at Low Institute for Therapeutics (LIFT). A 20-year healthcare veteran, he has extensive experience bringing novel pharmaceuticals and medical devices to market.
CO-founder and Executive Director
Stewart Low is the Executive Director at the Low Institute for Therapeutics (LIFT), where he leverages his extensive experience in advancing novel pharmaceuticals from academic research to clinical studies.
Co-Founder and Chairman of the Board
Dr. Philip Low is the Presidential Scholar for Drug Discovery and the RC Corley Distinguished Professor of Chemistry at Purdue University, where he directs a lab of ~35 graduate students/postdocs and ~50 undergraduate researchers.
Co-Founder and Founding Donor
Jeff Pickett is a Co-Founder at the Low Institute for Therapeutics (LIFT). He is the founder of Connor Group, a premier global professional services firm specializing in technical accounting, financial operations, and IPO services.
Co-Founder and Managing Director
Benjamin Lundgren is Managing Director at Low Institute for Therapeutics (LIFT). A 20-year healthcare veteran, he has extensive experience bringing novel pharmaceuticals and medical devices to market.
CO-founder and Executive Director
Stewart Low is the Executive Director at the Low Institute for Therapeutics (LIFT), where he leverages his extensive experience in advancing novel pharmaceuticals from academic research to clinical studies.
Co-Founder and Chairman of the Board
Dr. Philip Low is the Presidential Scholar for Drug Discovery and the RC Corley Distinguished Professor of Chemistry at Purdue University, where he directs a lab of ~35 graduate students/postdocs and ~50 undergraduate researchers.
Co-Founder and Founding Donor
Jeff Pickett is a Co-Founder at the Low Institute for Therapeutics (LIFT). He is the founder of Connor Group, a premier global professional services firm specializing in technical accounting, financial operations, and IPO services.
Co-Founder and Managing Director
Benjamin Lundgren is Managing Director at Low Institute for Therapeutics (LIFT). A 20-year healthcare veteran, he has extensive experience bringing novel pharmaceuticals and medical devices to market.
CO-founder and Executive Director
Stewart Low is the Executive Director at the Low Institute for Therapeutics (LIFT), where he leverages his extensive experience in advancing novel pharmaceuticals from academic research to clinical studies.
read about
The Low Institute for Therapeutics (LIFT) is a non-profit drug discovery institute dedicated to reducing human suffering and mortality through research and drug discovery.
Discover more publications >Because of upregulated expression on cancer-associated fibroblasts, fibroblast activation protein (FAP) has emerged as an attractive biomarker for the imaging and therapy of solid tumors.
Open link >An oligo-glutamate–conjugated abaloparatide homes to spinal fusion sites and, in rats, outperforms topical BMP-2—speeding mineralization, boosting fusion rates, and avoiding ectopic bone or toxicity.
Open link >Folate receptor delta (FRδ) has been used as a biomarker for regulatory T cells (Tregs), because its expression is limited to Tregs and ovum.
Open link >Because of upregulated expression on cancer-associated fibroblasts, fibroblast activation protein (FAP) has emerged as an attractive biomarker for the imaging and therapy of solid tumors.
Read more >An oligo-glutamate–conjugated abaloparatide homes to spinal fusion sites and, in rats, outperforms topical BMP-2—speeding mineralization, boosting fusion rates, and avoiding ectopic bone or toxicity.
Read more >Folate receptor delta (FRδ) has been used as a biomarker for regulatory T cells (Tregs), because its expression is limited to Tregs and ovum.
Read more >
work together
Join our exceptional team of specialists in such fields as business, science and technology and become a part of our innovative research group.
Search role for you >
News about us
Explore the latest updates on our research programs, grants, and emerging therapies developed at the Low Institute for Therapeutics. Follow the links to track progress and scientific breakthroughs from our teams.
Read more news >
Low Institute For Therapeutics
3000 Kent Ave, Suite 1956
West Lafayette, IN 47906
Low Institute For Therapeutics
3000 Kent Ave, Suite 1956
West Lafayette, IN 47906
